Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
JUBILANT PHARMOVA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
JUBILANT PHARMOVA Mar-23 |
ADCOCK INGRAM Jun-14 |
JUBILANT PHARMOVA / ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 496 | 314 | - | |
Low | Rs | 269 | 226 | - | |
Sales per share (Unadj.) | Rs | 394.4 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | -4.1 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 30.7 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 5.00 | 0 | - | |
Avg Dividend yield | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 338.6 | 73.3 | - | |
Shares outstanding (eoy) | m | 159.28 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.0 | 2.9 | 33.5% | |
Avg P/E ratio | x | -93.8 | -11.5 | 817.1% | |
P/CF ratio (eoy) | x | 12.4 | -13.9 | -89.8% | |
Price / Book Value ratio | x | 1.1 | 3.7 | 30.6% | |
Dividend payout | % | -122.7 | 0 | - | |
Avg Mkt Cap | Rs m | 60,873 | 45,603 | 133.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 21,660 | 2,862 | 756.8% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 62,817 | 15,761 | 398.6% | |
Other income | Rs m | 383 | 110 | 347.3% | |
Total revenues | Rs m | 63,201 | 15,872 | 398.2% | |
Gross profit | Rs m | 7,317 | -2,731 | -267.9% | |
Depreciation | Rs m | 5,540 | 680 | 814.5% | |
Interest | Rs m | 1,882 | 427 | 440.8% | |
Profit before tax | Rs m | 278 | -3,728 | -7.5% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 927 | 233 | 397.8% | |
Profit after tax | Rs m | -649 | -3,971 | 16.3% | |
Gross profit margin | % | 11.6 | -17.3 | -67.2% | |
Effective tax rate | % | 333.5 | -6.2 | -5,338.0% | |
Net profit margin | % | -1.0 | -25.2 | 4.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 37,624 | 11,544 | 325.9% | |
Current liabilities | Rs m | 17,724 | 6,495 | 272.9% | |
Net working cap to sales | % | 31.7 | 32.0 | 98.9% | |
Current ratio | x | 2.1 | 1.8 | 119.4% | |
Inventory Days | Days | 25 | 111 | 22.1% | |
Debtors Days | Days | 56 | 124 | 45.1% | |
Net fixed assets | Rs m | 71,668 | 6,729 | 1,065.1% | |
Share capital | Rs m | 159 | 73 | 217.4% | |
Net worth | Rs m | 53,931 | 12,371 | 436.0% | |
Long term debt | Rs m | 31,104 | 4,347 | 715.5% | |
Total assets | Rs m | 109,292 | 23,369 | 467.7% | |
Interest coverage | x | 1.1 | -7.7 | -14.8% | |
Debt to equity ratio | x | 0.6 | 0.4 | 164.1% | |
Sales to assets ratio | x | 0.6 | 0.7 | 85.2% | |
Return on assets | % | 1.1 | -15.2 | -7.4% | |
Return on equity | % | -1.2 | -32.1 | 3.7% | |
Return on capital | % | 2.5 | -19.8 | -12.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,607 | 1,345 | 491.1% | |
From Investments | Rs m | -5,444 | -413 | 1,317.9% | |
From Financial Activity | Rs m | -1,567 | 3,945 | -39.7% | |
Net Cashflow | Rs m | 301 | 4,878 | 6.2% |
Compare JUBILANT PHARMOVA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare JUBILANT PHARMOVA With: CONCORD DRUGS ALEMBIC THEMIS MEDICARE BIOFIL CHEMICALS GUJ.INJ(KER)
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.